coronary artery atherosclerosis is, multifactorial, complex disease locally, and a major cause of death in the United States. complex interaction between transport biochemical and biomechanical forces affecting the growth of the disease.
Wall shear stress (WSS) influence coronary artery atherosclerosis by inducing endothelial cell mechanotransduction and by controlling the near-wall transport processes involved in atherosclerosis. Each process is controlled by a different WSS and because it has complicated the interpretation of WSS in atherosclerosis. In this paper, we present a comprehensive theory for WSS in atherosclerosis.
First, a brief review of mechanotransduction shear stress-mediated atherosclerosis is presented. Next, a special subject of computational fluid dynamics (CFD) simulations performed on ten models of coronary artery diseased subjects and healthy. Specific biochemical mass transportation models developed for the study of low-density lipoprotein, nitric oxide, adenosine triphosphate, oxygen, monocyte chemoattractant protein-1, and transportation monocytes.
Results of transport compared to vector WSS and WSS Lagrangian coherent structures (WSS LCS). WSS high magnitude protected against atherosclerosis by increasing production or biochemical flux atheroprotective and reduce localization near-wall biochemistry atherogenic.
The amount of lower WSS promoted atherosclerosis by increasing localization of biochemical atherogenic. Finally, it’s interesting roles WSS SKB more complex where he was promoted or prevented by different biochemical atherosclerosis. We present a summary of the different pathways by which the WSS affect coronary artery atherosclerosis and compare mechanotransduction and biotransport different mechanisms.
Development of volatile organic compounds and their glycosylated precursors in tamarillo (Solanum betaceum Cav.) During fruit ripening: A prediction of biochemical pathways
key metabolites and pathways flavor-regulation in tamarillo investigated to explore the development of a free and glycosylation of volatile organic compounds (VOCs) during fruit ripening. The concentration of VOC-free and bound was determined by analysis by gas chromatography-mass spectrometry. Changes in physical parameters, the concentration of flavor precursors and key endogenous enzyme activity was also monitored.
A total of 22 VOC-free identified with C6 alcohols and esters into the main compound. Of the 83 VOCs detected glycosylation, phenols and terpenoids are the dominant component. The total concentration of VOCs is bound to increase up to four times during the ripening of fruit. Lipoxygenase pathway is confirmed as an important biosynthetic mechanism for the generation of VOC free and glycosylation during maturation tamarillo. This biosynthetic pathway is highly correlated with the activity of key enzymes and content of the substrate, especially of linolenic acid (p <0.05 or p <0.01).
Phenotypic, genotypic and biochemical changes during the selection of pyrethroid resistance in Anopheles gambiae mosquitoes
Directional Selection for insecticide resistance due to the indiscriminate use of insecticides in public health and agriculture system favors increased frequency of insecticide-resistant alleles in natural populations. Similarly, the removal of the selection pressure generally leads to rot in the resistance. recent investigations on the emergence of insecticide resistance in mosquitoes largely rely on field surveys resistance in vector populations that typically have a complex history of exposure to a variety of public health insecticides and pest control agricultural in nature, and thus the effects of certain insecticides on resistance levels level of emergency or resistance to decay unknown.
This study examined the phenotypic, genotypic, and biochemical changes that occur during the selection process for pyrethroid resistance in Anopheles gambiae, the most important vector of malaria in Africa. In parallel, we also examined the changes in the population hold when there is no selection pressure is applied.
Through repeated deltamethrin selection in adult mosquitoes from field populations collected in western Kenya for 12 generations, we obtain three independent and highly pyrethroid resistant An. gambiae populations. Three vulnerable populations from the same parent population is generated by removing the selection pressure.
Second row mosquito populations differ significantly in monooxygenases and beta-esterase activity, but not in Vgsc frequency of gene mutations, suggesting a metabolic detoxification mechanisms play a major role in generating resistance moderate intensity or high intensity resistance. Pre-exposure synergist piperonyl butoxide restored susceptibility to insecticides among highly resistant mosquitoes, confirming the role of monooxygenases in pyrethroid resistance.
The level of damage resistance to be fully susceptible of moderate intensity resistance took 15 generations, to support at least 2-year interval is required when using the rotation of insecticides with different modes of action to be considered for resistance management.
Biochemical parameters in Cognitive Function
cognitive impairment is a common disease. Many studies tried to elucidate the mechanisms of this dysfunction establishment, including the correlation between cognitive function and biochemical parameters. The scientists are looking for substances that will be an indicator of cognitive function and that can be determined in the cerebrospinal fluid or blood from subjects. Until now, they have isolated several such substances; However, research on the specificity of their validity and the possibility of their use in diagnostic and prognostic assessment is still ongoing.
However, there are only a few reports in the literature systematize the existing knowledge about this, and they are mostly associated with Alzheimer’s disease, not cognition in general, or refer only to certain groups of substances. This article discusses the most important biochemical exponent of cognitive function.
GALNT4 antibody |
|||
| 70R-7248 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal GALNT4 antibody |
|||
GALNT4 Antibody |
|||
| 1-CSB-PA009211GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GALNT4. Recognizes GALNT4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
|||
GALNT4 Antibody |
|||
| GWB-MQ133G | GenWay Biotech | 50ug | Ask for price |
GALNT4 Antibody |
|||
| GWB-MQ134H | GenWay Biotech | 50ug | Ask for price |
GALNT4 Antibody |
|||
| MBS858606-01mg | MyBiosource | 0.1mg | EUR 345 |
GALNT4 Antibody |
|||
| MBS858606-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GALNT4 Antibody |
|||
| MBS858606-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GALNT4 Antibody |
|||
| MBS858606-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GALNT4 Antibody |
|||
| MBS858606-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
GALNT4 Antibody |
|||
| MBS8503587-01mg | MyBiosource | 0.1mg | EUR 325 |
GALNT4 Antibody |
|||
| MBS8503587-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GALNT4 Antibody |
|||
| MBS8503587-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GALNT4 Antibody |
|||
| MBS8503587-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GALNT4 Antibody |
|||
| MBS8503587-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
GALNT4 Antibody |
|||
| MBS9611782-01mL | MyBiosource | 0.1mL | EUR 260 |
GALNT4 Antibody |
|||
| MBS9611782-02mL | MyBiosource | 0.2mL | EUR 305 |
GALNT4 Antibody |
|||
| MBS9611782-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
anti- GALNT4 antibody |
|||
| FNab03324 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against GALNT4 |
|||
GALNT4 Polyclonal Antibody |
|||
| E-AB-92585-120uL | Elabscience Biotech | 120uL | EUR 320 |
|
Description: Unconjugated |
|||
GALNT4 Polyclonal Antibody |
|||
| E-AB-92585-200uL | Elabscience Biotech | 200uL | EUR 530 |
|
Description: Unconjugated |
|||
GALNT4 Polyclonal Antibody |
|||
| E-AB-92585-60uL | Elabscience Biotech | 60uL | EUR 200 |
|
Description: Unconjugated |
|||
GALNT4 Polyclonal Antibody |
|||
| E-AB-92585-each | Elabscience Biotech | each | Ask for price |
|
Description: Unconjugated |
|||
GALNT4 Polyclonal Antibody |
|||
| MBS9126669-002mL | MyBiosource | 0.02mL | EUR 200 |
GALNT4 Polyclonal Antibody |
|||
| MBS9126669-005mL | MyBiosource | 0.05mL | EUR 255 |
GALNT4 Polyclonal Antibody |
|||
| MBS9126669-01mL | MyBiosource | 0.1mL | EUR 345 |
GALNT4 Polyclonal Antibody |
|||
| MBS9126669-02mL | MyBiosource | 0.2mL | EUR 545 |
GALNT4 Polyclonal Antibody |
|||
| MBS9126669-5x02mL | MyBiosource | 5x0.2mL | EUR 2265 |
GALNT4 Antibody (N-term) |
|||
| MBS9214580-008mL | MyBiosource | 0.08mL | EUR 210 |
GALNT4 Antibody (N-term) |
|||
| MBS9214580-04mL | MyBiosource | 0.4mL | EUR 430 |
GALNT4 Antibody (N-term) |
|||
| MBS9214580-5x04mL | MyBiosource | 5x0.4mL | EUR 1910 |
GALNT4 antibody - middle region |
|||
| MBS3207790-01mL | MyBiosource | 0.1mL | EUR 455 |
GALNT4 antibody - middle region |
|||
| MBS3207790-5x01mL | MyBiosource | 5x0.1mL | EUR 1995 |
GALNT4 antibody - C-terminal region |
|||
| MBS3207791-01mL | MyBiosource | 0.1mL | EUR 455 |
GALNT4 antibody - C-terminal region |
|||
| MBS3207791-5x01mL | MyBiosource | 5x0.1mL | EUR 1995 |
GALNT4 Antibody (N-term) Blocking peptide |
|||
| MBS9217473-INQUIRE | MyBiosource | INQUIRE | Ask for price |
ARP45527_P050-25UL - GALNT4 Antibody - middle region |
|||
| ARP45527_P050-25UL | Aviva Systems Biology | 25ul | EUR 99 |
ARP45527_P050 - GALNT4 antibody - middle region (ARP45527_P050) |
|||
| ARP45527_P050 | Aviva Systems Biology | 100ul | EUR 389 |
GALNT4 (N-term) Rabbit Polyclonal Antibody |
|||
| E10G30738 | EnoGene | 100 μl | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
GALNT4 |
|||
| CSB-CL836662HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
GALNT4 |
|||
| MBS8560494-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GALNT4 |
|||
| MBS8560494-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GALNT4 |
|||
| MBS8560494-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GALNT4 |
|||
| MBS8560494-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
GALNT4 |
|||
| MBS8560494-02mL | MyBiosource | 0.2mL | EUR 345 |
ARP45528_P050-25UL - GALNT4 Antibody - C-terminal region |
|||
| ARP45528_P050-25UL | Aviva Systems Biology | 25ul | EUR 99 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| 20-abx116519 | Abbexa |
|
|
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx122500-100ug | Abbexa | 100 ug | EUR 469.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx036817-100ug | Abbexa | 100 ug | EUR 469.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| 20-abx003143 | Abbexa |
|
|
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx025629-400ul | Abbexa | 400 ul | EUR 627.6 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx025629-80l | Abbexa | 80 µl | EUR 343.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx233324-100ug | Abbexa | 100 ug | EUR 610.8 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx116519-100g | Abbexa | 100 µg | EUR 612.5 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx122500-100l | Abbexa | 100 µl | Ask for price |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx122500-20l | Abbexa | 20 µl | EUR 337.5 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx122500-50l | Abbexa | 50 µl | Ask for price |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx036817-1096tests | Abbexa | 10 × 96 tests | Ask for price |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx036817-596tests | Abbexa | 5 × 96 tests | Ask for price |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx036817-96tests | Abbexa | 96 tests | EUR 337.5 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx025629-400l | Abbexa | 400 µl | EUR 518.75 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx233324-100g | Abbexa | 100 µg | EUR 350 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx003143-100l | Abbexa | 100 µl | EUR 400 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx003143-20l | Abbexa | 20 µl | EUR 175 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx003143-50l | Abbexa | 50 µl | EUR 275 |
ARP45528_P050 - GALNT4 antibody - C-terminal region (ARP45528_P050) |
|||
| ARP45528_P050 | Aviva Systems Biology | 100ul | EUR 389 |
GALNT4 siRNA |
|||
| 20-abx917540 | Abbexa |
|
|
GALNT4 siRNA |
|||
| 20-abx917541 | Abbexa |
|
|
GALNT4 Peptide |
|||
| MBS3232757-01mg | MyBiosource | 0.1mg | EUR 180 |
GALNT4 Peptide |
|||
| MBS3232757-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
GALNT4 Rabbit pAb |
|||
| A4243-100ul | Abclonal | 100 ul | EUR 369.6 |
GALNT4 Rabbit pAb |
|||
| A4243-200ul | Abclonal | 200 ul | EUR 550.8 |
GALNT4 Rabbit pAb |
|||
| A4243-20ul | Abclonal | 20 ul | Ask for price |
GALNT4 Rabbit pAb |
|||
| A4243-50ul | Abclonal | 50 ul | Ask for price |
GALNT4 cDNA Clone |
|||
| MBS1278040-001mgPlasmid02mLGlycerolStock | MyBiosource | 0.01mgPlasmid+0.2mLGlycerol-Stock | EUR 330 |
GALNT4 cDNA Clone |
|||
| MBS1278040-5x001mgPlasmid5x02mLGlycerolStock | MyBiosource | 5x0.01mgPlasmid+5x0.2mLGlycerol-Stock | EUR 1430 |
GALNT4 Rabbit pAb |
|||
| A4243 | Abclonal | 20μL | EUR 88.56 |
GALNT4 siRNA (Mouse) |
|||
| MBS8233244-15nmol | MyBiosource | 15nmol | EUR 405 |
GALNT4 siRNA (Mouse) |
|||
| MBS8233244-30nmol | MyBiosource | 30nmol | EUR 565 |
GALNT4 siRNA (Mouse) |
|||
| MBS8233244-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
GALNT4 siRNA (Human) |
|||
| MBS8236804-15nmol | MyBiosource | 15nmol | EUR 405 |
GALNT4 siRNA (Human) |
|||
| MBS8236804-30nmol | MyBiosource | 30nmol | EUR 565 |
GALNT4 siRNA (Human) |
|||
| MBS8236804-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
GALNT4 cloning plasmid |
|||
| CSB-CL836662HU-10ug | Cusabio | 10ug | EUR 451.2 |
|
Description: A cloning plasmid for the GALNT4 gene. |
|||
GALNT4 Blocking Peptide |
|||
| 33R-1400 | Fitzgerald | 100 ug | EUR 119 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GALNT4 antibody, catalog no. 70R-7245 |
|||
GALNT4 Blocking Peptide |
|||
| 33R-9559 | Fitzgerald | 100 ug | EUR 119 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GALNT4 antibody, catalog no. 70R-7248 |
|||
GALNT4 Blocking Peptide |
|||
| DF13031-BP | Affbiotech | 1mg | EUR 234 |
GALNT4 Blocking Peptide |
|||
| MBS9621735-1mg | MyBiosource | 1mg | EUR 380 |
GALNT4 Blocking Peptide |
|||
| MBS9621735-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
Mouse Galnt4 ELISA KIT |
|||
| ELI-27156m | Nova Lifetech | 96tests | EUR 736 |
Human GALNT4 ELISA KIT |
|||
| EF009763 | Nova Lifetech | 96tests | EUR 566 |
Human GALNT4 ELISA KIT |
|||
| ELI-30796h | Nova Lifetech | 96tests | EUR 696 |
Mouse GALNT4 shRNA Plasmid |
|||
| 20-abx970459 | Abbexa |
|
|
Human GALNT4 shRNA Plasmid |
|||
| 20-abx955721 | Abbexa |
|
|
Human GALNT4 Protein Lysate |
|||
| MBS8412092-002mg | MyBiosource | 0.02mg | EUR 365 |
Human GALNT4 Protein Lysate |
|||
| MBS8412092-5x002mg | MyBiosource | 5x0.02mg | EUR 1410 |
GALNT4 Peptide - middle region |
|||
| MBS3232756-01mg | MyBiosource | 0.1mg | EUR 180 |
GALNT4 Peptide - middle region |
|||
| MBS3232756-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
GALNT4 Recombinant Protein (Rat) |
|||
| RP202175 | ABM | 100 ug | Ask for price |
AAP45528-100UG - GALNT4 Peptide |
|||
| AAP45528-100UG | Aviva Systems Biology | 100ug | EUR 99 |
GALNT4 Recombinant Protein (Human) |
|||
| RP012883 | ABM | 100 ug | Ask for price |
GALNT4 Recombinant Protein (Mouse) |
|||
| RP135836 | ABM | 100 ug | Ask for price |
GALNT4 (N-term) Rabbit pAb |
|||
| E2611166 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Galnt4 ORF Vector (Rat) (pORF) |
|||
| ORF067393 | ABM | 1.0 ug DNA | EUR 607.2 |
GALNT4 (N-Term) Rabbit pAb |
|||
| MBS8551209-01mL | MyBiosource | 0.1mL | EUR 305 |
GALNT4 (N-Term) Rabbit pAb |
|||
| MBS8551209-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GALNT4 (N-Term) Rabbit pAb |
|||
| MBS8551209-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GALNT4 (N-Term) Rabbit pAb |
|||
| MBS8551209-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GALNT4 (N-Term) Rabbit pAb |
|||
| MBS8551209-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Galnt4 ORF Vector (Mouse) (pORF) |
|||
| ORF045280 | ABM | 1.0 ug DNA | EUR 607.2 |
GALNT4 ORF Vector (Human) (pORF) |
|||
| ORF004295 | ABM | 1.0 ug DNA | EUR 114 |
Human GALNT4 knockout cell line |
|||
| ABC-KH5887 | AcceGen | 1 vial | Ask for price |
|
Description: Human GALNT4 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human GALNT4 knockdown cell line |
|||
| ABC-KD5887 | AcceGen | 1 vial | Ask for price |
|
Description: Human GALNT4 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human GALNT4 Protein Lysate 20ug |
|||
| IHUGALNT4PLLY20UG | Innovative research | each | EUR 213 |
|
Description: Human GALNT4 Protein Lysate 20ug |
|||
GALNT4 (NM_003774) Human Over-expression Lysate |
|||
| LS008693 | BosterBio | 100ug | EUR 628 |
|
Description: Transient overexpression lysate of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4) (GALNT4) |
|||
OCOA13442-20UG - GALNT4 Protein Lysate |
|||
| OCOA13442-20UG | Aviva Systems Biology | 20ug | EUR 169 |
GALNT4 Over-expression Lysate Product |
|||
| GWB-EC88F1 | GenWay Biotech | 0.1 mg | Ask for price |
Galnt4 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7515601 | ABM | 3 x 1.0 ug | EUR 406.8 |
GALNT4 sgRNA CRISPR Lentivector set (Human) |
|||
| K0835401 | ABM | 3 x 1.0 ug | EUR 406.8 |
Galnt4 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3418201 | ABM | 3 x 1.0 ug | EUR 406.8 |
Galnt4 (GFP-tagged) - Mouse UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (Galnt4) |
|||
| MG209072 | Origene Technologies GmbH | 10 µg | Ask for price |
Galnt4 (untagged) - Mouse UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (Galnt4), (10ug) |
|||
| MC202379 | Origene Technologies GmbH | 10 µg | Ask for price |
GALNT4 3'UTR GFP Stable Cell Line |
|||
| TU058523 | ABM | 1.0 ml | EUR 2799.6 |
Galnt4 3'UTR GFP Stable Cell Line |
|||
| TU254930 | ABM | 1.0 ml | Ask for price |
Galnt4 3'UTR GFP Stable Cell Line |
|||
| TU156887 | ABM | 1.0 ml | Ask for price |
GALNT4 (untagged)-Human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4) (GALNT4) |
|||
| SC117755 | Origene Technologies GmbH | 10 µg | Ask for price |
AAP45527-100UG - GALNT4 Peptide - middle region |
|||
| AAP45527-100UG | Aviva Systems Biology | 100ug | EUR 99 |
GALNT4 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV269572 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPB-C-His) |
|||
| PV269570 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPB-N-His) |
|||
| PV269571 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPM-C-His) |
|||
| PV269573 | ABM | 500 ng | EUR 723.6 |
Galnt4 (Myc-DDK-tagged) - Mouse UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (Galnt4) |
|||
| MR209072 | Origene Technologies GmbH | 10 µg | Ask for price |
GALNT4 Protein Vector (Human) (pPM-C-HA) |
|||
| PV017179 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV181120 | ABM | 500 ng | EUR 723.6 |
Galnt4 3'UTR Luciferase Stable Cell Line |
|||
| TU204930 | ABM | 1.0 ml | Ask for price |
GALNT4 3'UTR Luciferase Stable Cell Line |
|||
| TU008523 | ABM | 1.0 ml | EUR 2799.6 |
GALNT4 Protein Vector (Human) (pPB-C-His) |
|||
| PV017177 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Human) (pPB-N-His) |
|||
| PV017178 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Human) (pPM-C-His) |
|||
| PV017180 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV181118 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV181119 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV181121 | ABM | 500 ng | EUR 723.6 |
Galnt4 3'UTR Luciferase Stable Cell Line |
|||
| TU106887 | ABM | 1.0 ml | Ask for price |
GALNT4 (GFP-tagged) - Human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4) (GALNT4) |
|||
| RG207176 | Origene Technologies GmbH | 10 µg | Ask for price |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7515602 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7515603 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7515604 | ABM | 1.0 ug DNA | EUR 184.8 |
Human GALNT4 Over-expressing Stable Cell Line |
|||
| ABC-X1191 | AcceGen | 1 vial | Ask for price |
|
Description: Gentaur can provide custom lentiviral constructs expressing any genes of interest as long as it is less than about 3 kb. Lentiviral technology enables us to efficiently generate stable expression lines which are then selected for moderate or high expressers, depending on the experimental requirements. If you are interested in specific lentiviral DNA constructs or have further questions, please contact us to discuss the details. GALNT4 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4) [ Homo sapiens ] http://www.ncbi.nlm.nih.gov/gene/8693 |
|||
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0835402 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0835403 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0835404 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3418202 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3418203 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3418204 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 (Myc-DDK-tagged)-Human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4) (GALNT4) |
|||
| RC207176 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, Galnt4 (GFP-tagged) - Mouse UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (Galnt4), 200 |
|||
| MR209072L4V | Origene Technologies GmbH | 200 µl | Ask for price |